Vast Therapeutics

Coming – October 21

A Billion-Dollar Opportunity In Treating Lung Infections

Date and Time

October 21

–

12:00 PM ET / 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Vast Therapeutics is pioneering a transformational approach to treating chronic and life-threatening respiratory infections. The standard of care in many lung diseases is inadequate leading to poor quality of life for many patients, especially cystic fibrosis (CF). At the core of Vast’s innovation is ALX1, a first-in-class inhaled therapy that replenishes nitric oxide (NO) in the lungs, restoring the body’s natural defense against infection and inflammation.

Initial studies are targeting a high-priority pathogen that causes over 500,000 deaths annually worldwide. Current standard-of-care antibiotics cannot eradicate this resilient bacteria and are subject to resistance. In preclinical studies, ALX1 demonstrated 99.9% bacterial reduction and complete eradication in most of the animals tested. Importantly, ALX1’s dual antimicrobial and anti-inflammatory mechanisms position it for continuous use without fostering resistance.

The near-term focus is on CF, but ALX1’s potential extends across a $90B respiratory therapeutics market, that includes patients with non-CF bronchiectasis, COPD, and hospital-acquired pneumonia.

Register today to join our online event with Nate Stasko, CFO of Vast Therapeutics, to hear how the company is uniquely positioned for significant value creation and offers multiple liquidity pathways.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.